Exosome Diagnostics Appoints Accomplished Urologist, Grannum Sant, MD, FRCS, FACS, as Head of Medical Affairs

Waltham, MA, March 21, 2018 (GLOBE NEWSWIRE) -- Exosome Diagnostics, Inc., is thrilled to announce the appointment of Dr. Grannum Sant as Head of Medical Affairs.  As an internationally recognized clinician and pharma executive with extensive experience in Diagnostics, Companion Diagnostics and Therapeutics, he is a powerful addition to the Exosome Diagnostics team. 

In his more than two decades with Tufts University, Dr. Sant served as Professor and Chair of Urology at Tufts University School of Medicine, where he still holds an appointment as Professor of Urology. While at Tufts, Dr. Sant proved himself as an international expert in urology and urologic oncology, which led to numerous leadership positions within research and professional societies.  This includes a term as President of the New England Section of the American Urological Association. In addition to his impressive experience within clinical urology, Dr. Sant made an international name for himself as a pharma medical affairs and clinical development executive; serving as VP Medical Affairs for Oncology/Urology at Sanofi-Aventis US, VP and Head of Medical Affairs for Rare Diseases at Genzyme.  Most recently, Dr. Sant was Medical Affairs Lead for OPKO Health Inc.

Having very successfully launched eight unique diagnostics and therapeutics, Dr. Sant is eager to translate his extensive research and industry experience into the continued success of Exosome Diagnostics’ flagship test, ExoDx Prostate(IntelliScore)® or EPI, the world’s first and only exosomal RNA based diagnostic developed to reduce the amount of unnecessary prostate biopsies. “I am honored to join the Exosome Diagnostics team with its focus on science and commitment to improving the lives of patients. EPI is a stand-out urologic diagnostic with clear clinical utility,” said Dr. Sant. “With the unparalleled power of its platform, Exosome Diagnostics’ potential is unmatched, and I am excited to join Exosome’s strong, motivated and dynamic team” Sant concluded.

“Exosome Diagnostics has focused much of the last year setting a new precedent in both diagnostic market adoption and reimbursement strategy, making EPI a clear stand-out in this space,” Elizabeth Cormier-May, Vice President and Head of Commercial Diagnostics shared.  “The addition of Dr. Sant to our team is another substantial milestone for us, as he will bring multiple layers of value to our rapidly expanding urology franchise,” Cormier-May continued.

“Dr. Sant’s rare combination of urology, diagnostics, and pharma experience makes him an ideal fit for Exosome Diagnostics,” stated John Boyce, President and CEO of Exosome Diagnostics.  “Dr. Sant will play a pivotal role in the development of the diagnostic urology franchise, by overseeing the advancement of a significant number of validated liquid biopsy diagnostic tests in the Exosome pipeline,” Boyce continued. “Given Dr. Sant’s extensive pharmaceutical experience, he will work closely with the company’s companion diagnostics group and pharmaceutical partners to further the company’s diagnostic drug development expertise. We are honored to have Dr. Sant on board,” Boyce concluded.  

Dr. Sant will attend his first conference as Head of Medical Affairs for Exosome Diagnostics at the Southeast Section of the American Urological Association meeting on March 20-25, 2018 in Orlando, FL.

About Exosome Diagnostics

Exosome Diagnostics is a privately held company focused on developing and commercializing revolutionary biofluid-based diagnostics to deliver personalized precision healthcare that improves lives. The company’s novel exosome-based technology platform, ExoLution™, and point of care instrument for protein capture and analysis, Shahky™, can yield comprehensive and dynamic molecular insights to transform how cancer and other serious diseases are diagnosed, treated and monitored.

Visit www.exosomedx.com to learn more.


A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/3e1f3696-b44c-4930-bdf1-567fdfa8529f


Contact Data